Blog Posts
May 11, 2021

Spatial Spotlights LARVOL’s #VRFirst, #RemoteAlways Culture

Blog Posts
May 11, 2021

Spatial Spotlights LARVOL’s #VRFirst, #RemoteAlways Culture

Author

In our VR offices, co-workers who are thousands of miles apart can finally meet via Spatial’s 3D avatar system.

Since 2004, LARVOL has delivered intelligence, analysis, and software solutions to the most prominent pharmaceutical companies in the world. With a global team that lives and works in 14 countries, LARVOL has always been remote. Over the years, we have consistently delivered excellent results to our customers and maintained a strong company culture without a physical office for our team.

Virtual Reality (VR) now offers an amazing opportunity for LARVOL teammates, or “Tigers,” to keep in touch and collaborate on projects from our remote home offices. LARVOL is utilizing the VR platform Spatial as our virtual “office space.” We recently announced our commitment to being “VR first,” which means we now hold the majority of our meetings and business interactions in “the metaverse.” The Spatial team stopped by our virtual offices to learn more about this decision, as we are the first company to take such a step.

In our VR offices, co-workers who are thousands of miles apart can finally meet via Spatial’s 3D avatar system. Avatars are built using team members’ selfies, and they move, speak, and interact with their environment and other Tigers. Spatial allows for a much greater degree of personal interaction and immediate camaraderie than is possible during a video call. For those who are new to a corporate environment, the virtual office offers a unique chance to adapt to office norms and learn the dynamics of collaboration with a group. In addition, the headsets help cut down on distractions so that team members can better focus on the meeting.

During meetings, team members can move around the room, write signs or draw, clap their hands, make presentations from their computer screen, and even take pictures of the room, including selfies. It’s a dynamic environment that keeps energy high and ideas flowing.

At any time of day, teammates from around the world may be meeting in one of the Spatial rooms. The always-open virtual office helps LARVOL to overcome the challenges of different time zones and the high cost of business travel, which hasn’t even been an option during the pandemic.

In order to help all our Tigers make the leap into VR, we’re in the process of sending each of our Tigers an Oculus Quest 2 headset so they can fully participate in our Spatial meetings. This new way of staying connected will strengthen and unite our Tiger team more than ever before, and we’re excited to be the first company to work in the metaverse!

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.